The second face-to-face RBDCOV meeting is taking place today at Palau Macaya in Barcelona! Our expert, Chris Mann, is attending the meeting in person.
After 14-months of working on the project, the consortium members are meeting today to put together the latest developments about the new COVID19 vaccine for children, adolescents and immunocompromised people using a recombinant protein. RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the variants of COVID19.
Asphalion is proud regulatory partner of RBDCOV by carrying out the regulatory pathway throughout the project: seeking scientific advice for the RBDCOV clinical trials with the European regulatory authorities; preparing the required documents to support clinical trial applications and supporting the preparation of the eCTD registration dossier, among other regulatory activities.
Our participation in several EU-funded, cutting-edge projects allows us to be at the forefront of innovation and are an added value to our know-how, heightening our position in the COVID-19 vaccine development.
For more details about the project, have a look at the project´s website: https://rbdcov.eu/